Back to the screen
LXEO
Lexeo Therapeutics, Inc.
Biotechnology · Healthcare · United States
3.11
close · Nov 3, 2026
value
24
cheaper than peers24
quality
64
stronger fundamentals64
ranked against
Biotechnology (pre-revenue)
value · 9 inputs
quality · 3 inputs
110 peerswide variation
Value inputs
| measure | company | vs peers |
|---|---|---|
| price to book | 1.04× | 75 |
| earnings yield, 3 years ago | -75.7% | 45 |
| cash flow yield, 2 years ago | -23.4% | 42 |
| cash flow yield, 3 years ago | -21.7% | 41 |
| cash flow yield, 1 year ago | -32.0% | 39 |
| cash flow yield, latest year | -38.8% | 31 |
| earnings yield, latest year | -59.8% | 29 |
| earnings yield, 1 year ago | -99.4% | 23 |
| earnings yield, 2 years ago | -398.7% | 9 |
9 of 12 measures available
Quality inputs
| measure | company | vs peers |
|---|---|---|
| return on equity | -46.8% | 67 |
| debt to equity | 2.9% | 55 |
| operating margin | 0.0% | 50 |
3 of 4 measures available
Facts
| market cap | $255M |
|---|---|
| free cash flow | -$58.8M |
| employees | 63 |
| first trade | Nov 3, 2023 |
| next earnings | Aug 12, 2026 |
| fundamentals updated | Aug 20, 2026 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| diluted eps | -1.86 | -3.09 | -12.40 | -2.36 | not reported |
| free cash flow | -$99.0M | -$81.6M | -$59.7M | -$55.5M | not reported |
| net income | -$100.0M | -$98.3M | -$66.4M | -$59.3M | not reported |
| revenue | $0 | $0 | $0 | $654,000 | not reported |
| unusual items | $3.4M | not reported | -$530,000 | not reported | $0 |